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| INTRODUC TI ON
Patients with a first venous thrombosis (VT; the composite of deep vein thrombosis [DVT] and pulmonary embolism) have a high risk of a recurrent event.
1,2 Anticoagulant therapy is effective for treating a first event as well as for preventing a recurrence. Trials have shown that 3 months of anticoagulant therapy is the minimum duration of initial treatment. 3 However, it is uncertain whether anticoagulant treatment should be continued beyond this period to prevent recurrences. This uncertainty arises from the associated risk of this treatment, that is severe bleeding. 4, 5 Both recurrent VT and major bleeding are serious events, with case-fatality rates ranging between 4% and 10%. 6, 7 The decision on treatment duration has strong lifelong implications, as the cumulative thrombosis and bleeding risks will become high over a person's lifetime. Nevertheless, the propensity to develop recurrent VT or bleeding differs strongly between individuals, depending on their genetic makeup and environmental circumstances. 8 Attempts have been made to quantify these risks at an individual level as a basis for predicting the risk. The three best known prediction models for VT, that is, the Men continue and HERDOO2 rule, the Vienna prediction model, and the DASH score, are exclusively aimed at patients with an unprovoked first event (about 30%-50% of the total VT population, depending on the definition of unprovoked).
9-11
External validation studies showed less discriminative ability than the original studies. [12] [13] [14] In the HERDOO2 study, authors confirmed that women with a first unprovoked VT and none or one of the HERDOO2 criteria could safely discontinue anticoagulants after completing shortterm treatment. 15 Nevertheless, the majority of their population could not be classified in this low-risk group (n = 2125; 76%).
The current guidelines advise to classify all patients in only two groups, with either high or low risk of VT recurrence. 16, 17 This classification is based on one determinant, that is, whether the index event was provoked by a transient risk factor or whether it was unprovoked.
Roughly speaking, the provoked/low-risk group is advised to stop anticoagulant treatment and the unprovoked/high-risk group is advised to continue if the associated bleeding risk is expected to be low to moderate. 16 One problem with this approach is that the definition of (un)provoked is unclear and varies between centers and over time. 18 We aimed to validate the DASH and Vienna prediction models for recurrent VT externally within the MEGA follow-up study. Since in MEGA HemosIL D-dimer was performed rather than VIDAS D-dimer, 19 and symptoms of posttraumatic stress were self-reported in MEGA, we did not validate HERDOO2. Furthermore, we determined the effect of using different definitions for "unprovoked." Last, we estimated the absolute risk of recurrence based on individual combinations of characteristics currently regarded to have the strongest predictive value. 
| ME THODS

| Patient population
| Recurrent venous thrombosis
Questionnaires concerning recurrent venous thrombosis were sent by mail to all survivors and consenting individuals between June 2008
and July 2009, and supplemented by telephone interviews. Additional information was acquired from the regional anticoagulation clinics and from hospitals. Deaths resulting from recurrent venous thrombosis were counted as fatal recurrent events. On the basis of hospital discharge letters, the information from the anticoagulation clinic, questionnaires filled in by the patients, and causes of death, possible recurrences were classified into certain and uncertain recurrences, following a decision rule. 21 Patients with uncertain recurrent events were censored from this event onward. Censoring uncertain events decreases non-differential misclassification, although excluding uncertain recurrent events could have resulted in a lower-than-expected recurrent VT rate, which may have affected the performance of the model to some extent.
| Blood sampling and laboratory analyses
Approximately 3 months after discontinuation of oral anticoagulant therapy, patients were invited for collection of a blood
Essentials
• Prediction models for recurrent VT need external validation to establish clinical usefulness.
• Vienna and DASH models were externally validated in the MEGA follow-up study.
• These models were moderately able to distinguish in recurrence risks.
• The definition of "unprovoked" first events strongly influenced the predictive performances.
sample. When they were still on anticoagulant therapy 1 year after their event, blood was drawn during treatment. 
| Statistical analyses
Follow-up started at time of discontinuation of anticoagulant treatment similar to the development studies of the three prediction models. Patients diagnosed with cancer within 5 years before VT or patients with missing data on cancer were excluded, also following the original studies. All other patients with VT were included regardless of the presence or absence of risk factors. All analyses (see later discussion) did, however, make a sharp distinction between provoked and unprovoked first events as Vienna and DASH only included unprovoked events. The end of follow-up was defined as the date of a recurrent event and, in the absence of a recurrence, the date of filling in the short questionnaire. 21 If a patient did not fill in the questionnaire he or she was censored at the last date we knew the patient was recurrence-free. This could be either the last visit to the anticoagulant clinic, the date of death or emigration, or the last moment the patient was known to be recurrence-free from information of the MEGA case-control study. Duration of follow-up was calculated by starting follow-up at the date of discontinuation of anticoagulant therapy.
| (A) External validation of currently available models
We validated the Vienna model and the DASH score. Predictor variables included were D-dimer (Vienna, DASH), age (DASH), sex (Vienna, DASH), site of index event (Vienna), and hormone therapy (DASH). Since the performance of a prediction model depends on the patient population included, and the two models used different definitions of unprovoked VT, we aimed to validate the models in two ways: (a) by using the original study's criteria for unprovoked events and (b) by using our own criteria for unprovoked VT, which were: VT without surgery, trauma, plaster cast, pregnancy or immobilization in the first 3 months before the event,
prolonged travel in the first 2 months before the event, and hormone use (oral contraceptives or hormone replacement therapy)
at the time of the event. For the selection of patients with an unprovoked first event according to various definitions we were dependent on variables that were available in MEGA; that is, we did not know whether patients had positive lupus anticoagulants, positive anticardiolipin antibodies, or positive antiphospholipid antibodies (exclusion criteria for Vienna and DASH, respectively).
Furthermore, blood samples were available for 51% of the population as we ceased collecting halfway during the study. This means that we could select only half of the population according to the 
| (B) Risk stratification
To study whether further refined risk estimation is possible within the two risk groups that are currently distinguished, we estimated recurrence rates in six groups of patients, according to some well-described 
| RE SULTS
A total of 715 patients were excluded because their follow-up ended before or at the moment of discontinuation of anticoagulant treatment. An additional 266 patients were excluded because of a cancer diagnosis or missing data on cancer, leading to a total of 3750 patients (Figure 1 ). Their main characteristics are provided in Table 1 , overall and categorized by model. As can be observed, the age at time of first VT, percentage of women, and high D-dimer levels differed strongly according to the definitions applied.
During a median follow-up of 5.7 (interquartile range 3.2-7.4) years, 600 certain recurrent events occurred, for an incidence rate of 3.1 (95% CI, 2.9-3.4) per 100 patient-years ( Table 2 ). The recurrence rate was 5.2 (95% CI, 4.6-5.9) per 100 patient-years in those who had a first unprovoked VT according to our definition, while it was 3.4 per 100 patient-years for the Vienna model and 3.8 per 100
patient-years for the DASH prediction rule.
In Table 3 , we show the results of the external validation of the two prediction models. The C-statistic was 0.62 for Vienna and 0.66 for DASH. We also observed that the C-statistic declined to 0.61 for Vienna and 0.56 for DASH when we used our definition of unprovoked VT. Results were similar in a sensitivity analysis where we included patients with missing data on cancer at time of VT and where we imputed data of patients who had missing D-dimer levels.
As can be observed from Table 4 , the observed risks in MEGA more or less followed the predicted risks in Vienna and DASH, although absolute risks were lower in MEGA as compared with the development studies.
13,14 
F I G U R E 1
Flowchart of the MEGA follow-up study. Of analyzed patients, there were 336 (9%) lost to follow-up. They were analyzed until the moment they were lost to follow-up. *Of these patients there were 52 who had a recurrent event before blood sampling 
| D ISCUSS I ON
This validation study of two previously established prediction models for recurrent VT shows that their ability to distinguish recurrence risks was lower than in the original studies. [8] [9] [10] This is not surprising since validation studies usually show more conservative results as they were not optimized for the data from which they were originally derived. Nevertheless, although the C-statistics were lower, they all confirmed the robustness of the prediction models, despite differences in patient characteristics in the co- and what is not an unprovoked event should be standardized and universally applied. 18 Alternatively, and preferable in routine patient care, it could be considered to develop and use models that apply to all patients with a first event, without determining whether it was unprovoked or not.
Our results also showed that the absolute risk of recurrence 
TA B L E 3 External validation of three prediction models
Main analysis
Harrell's C-statistic (95% CI) One limitation is that our findings are only in part generalizable to DASH and Vienna since the follow-up time between MEGAfollow-up and these studies differed. Although a longer follow-up usually leads to lower yield of correct prediction, the Vienna model showed that risk of recurrent VT can be predicted from multiple random time points up to 5 years of follow-up, 22 so a negative effect of longer follow-up is expected to be limited. venous thrombosis. 19 Furthermore, the results on risk stratification should be seen as illustrative only and not confirmative, as for this aim, one would need to build a new risk model, which is beyond the scope of the present study. Our validation study has focused strongly on the C-statistic. It should be mentioned that the assumption that a model only works well if the C-statistic is high is flawed since the C-statistic only describes how well models can rank order high-risk patients and low-risk patients, but is not a function of the actual predicted probabilities, as we also explain in an accompanying Forum article. 26 Nevertheless, much of risk prediction was determined by the definition of "unprovoked," which suggests that there is much to gain when universal definitions of unprovoked events are applied or when a definition is not applied at all (i.e. all patients with VT events are considered to be at risk of recurrence).
Development set
External
In summary, this validation study showed that predicting the risk of unprovoked recurrent VT is possible to some extent with the currently available models, but that their predictive performance is lower than in the original studies. The predictive ability is strongly influenced by the definition of unprovoked VT. Furthermore, risks of recurrence clearly vary in patients with provoked events according to presence of risk factors for recurrence. This implies that the current policy of classifying recurrence risk on the basis of whether the first event was (un)provoked is too crude and should be reconsidered. In an accompanying Forum paper, 26 we present solutions as to how a more-refined risk estimation is possible at an individual level in patients at risk of recurrent venous thrombosis. or the decision to submit the manuscript for publication. J. F. Timp had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analyses.
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